Market Report Source

Overview

Drug delivery is one of the most dynamic and fast growing sectors of the
pharmaceutical industry. The high level of innovation in this sector is
evolving at a fast pace with products such as Pfizer’s inhaled insulin,
Exubera, gaining US approval in January 2006.

‘Innovation in Drug Delivery’ provides an in-depth examination of
product launches and pipeline drugs with novel drug delivery
mechanisms set to revolutionize the market, such as products using
ALZA Corporation’s E-TRANS and Altea’s PassPort patch transdermal
technologies. This report will enable you to evaluate key marketed drugs,
including Emend and Megace, and gain an insight into novel pipeline
products to anticipate upcoming product launches and position yourself
for success.

Use this report to understand how nanotechnology and other key
technologies are changing drug delivery and how these can be
implemented into your R&D process. Assess the impact of innovation in
therapy areas including oncology, diabetes and infectious diseases and
identify future opportunities for market growth.

Some key findings from this report…
• Solubility is a key resistor to drug delivery and a major factor
causing attrition and poor efficacy in drug development, with an
estimated 30% of drugs in pre-clinical development having low
solubility.
• Abraxane and Doxil are both innovative marketed oncology
products utilizing nanotechnology, gaining sales of $184m and $177m
in the US and 5 major European countries in 2005, respectively.
• There are several high potential inhaled monoclonal antibodies in
development, including products from Enzon and Nektar, Alexion and
Medimmune, and Alkermes.
• Active transdermal patches are predominantly indicated for pain and
women’s health, but products using ALZA’s E-TRANS and Altea’s
PassPort patch technology are predicted to available for protein
delivery within the next few years, and consequently will increase the
range of accessible indications for transdermal delivery.
• Drug eluting stents are typically 3 to 4 fold more expensive than bare
metal stents and have elicited safety concerns, however next
generation drug-eluting stents consist of bio-absorbable polymers
and are predicted to be safer.

Key questions answered in this report
• What are the key drivers of innovation in drug delivery and how are
they impacting the pharmaceutical market?
• How is nanotechnology driving forward innovation and what is its
impact on each therapy area?
• What strategies are the leading drug delivery companies
implementing to maximize sales and boost market share?
• Who are the leading innovators in transdermal and pulmonary drug
delivery?
• Which new product launches will gain high sales and challenge the
current market leaders?
• What are the key trends in drug delivery and how will they impact
future sales?
• Which innovative drug delivery technologies have the highest future
potential?

Top five reasons to order your copy today
• Understand how nanotechnology is revolutionizing drug delivery and
how this can be implemented into your own R&D process.
• Evaluate key marketed drugs with innovative drug delivery and gain
insight into novel pipeline products to identify your competitive
position and anticipate upcoming product launches.
• Gain access to the latest information on key technologies in drug
delivery, with the report’s comprehensive coverage of leaders in
each field.
• Assess the impact of innovation in drug delivery in therapy areas
including oncology, diabetes and infectious diseases and identify
future opportunities for market growth.
• Implement strategies to address the key unmet needs in drug
delivery and current and future challenges in key indications,
enabling you to plan for future success.

Table of Contents

Executive Summary

Introduction

Advances in nanotechnology

Targeted therapies in oncology

Innovation in pulmonary delivery

Innovation in transdermal delivery

Innovation in medical devices: stents and implants

Competitive landscape

The future of drug delivery

Chapter 1 Introduction

Summary

Introduction

Key indications

Key trends

Cost and revenue implications of innovative technology

Drivers of innovation

Poor patient compliance and injectable protein delivery

Needle-free injections

Non-invasive protein delivery

Poor solubility

Formulation technologies for poorly soluble compounds

Reducing drug dosage frequency

Combination products

Controlled release

Conclusions and key findings

Chapter 2 Advances in nanotechnology

Summary

Introduction

Advantages of nanotechnology for drug delivery

Marketed products using nanotechnology

Abraxane

Doxil

Potential for nanotechnology in drug delivery

Injectable delivery

Implantable delivery systems

Oral delivery

Transdermal delivery

Competitive landscape

Elan

Flamel Technologies

Michigan Nanotechnology Institute for Medicine and Biological Sciences

Abraxis BioScience

Others

The future of nanotechnology in drug delivery

Delivering cancer stem cell therapies

siRNA and gene therapy

Conclusions and key findings

Chapter 3 Targeted therapies in oncology

Summary

Introduction

Targeted therapies overview

Nanotechnologies to target cancers

Stealth

Transdrug

NanoCrystal

Monoclonal antibodies

Pipeline mAbs

Antibody fragments

PEGylation

UniBody technology

Inhaled monoclonal antibodies

Oral monoclonal antibodies

Drug delivery to brain tumors

Stem cell therapy

Synthetic toxins

Viral delivery systems

RNAi in chemotherapy

Conclusions and key findings

Chapter 4 Innovation in pulmonary delivery

Summary

Introduction

Advantages and disadvantages of pulmonary delivery

Advantages

Disadvantages

Key pulmonary delivery pipeline

Key indications for pulmonary drug delivery

Asthma and COPD

Diabetes

Inhaled insulin pipeline

CNS disorders

Infectious diseases

Other indications

Conclusions and key findings

Chapter 5 Innovation in transdermal delivery

Summary

Introduction

Transdermal drug delivery pipeline

Transdermal patch technologies

Passive patch

Noven Pharmaceuticals

Iomai

Active patches

ZARS Pharma

ALZA Corporation

Altea Therapeutics

TransPharma Medical

Future of transdermal drug delivery

Conclusion and key findings

Chapter 6 Innovation in medical devices: stents and implants

Summary

Introduction

Implants

Injectable solid implants

Injectable microparticles

Drug-eluting stents

Marketed stents

Cypher

Taxus

Xience

Clinical trials

Cost effectiveness

Adverse events

Drug-eluting stent pipeline

ZoMaxx

Endeavor

Next generation drug-eluting stents

Controlled-release implantable microchips

MEMS technologies

Conclusions and key findings

Chapter 7 Competitive landscape

Summary

Introduction

Leading innovative drug delivery companies

Altea Therapeutics

Pipeline

Strategic and growth analysis

ALZA Corporation

Pipeline

Strategic and growth analysis

Elan

Pipeline

Strategic and growth analysis

Emisphere

Pipeline

Strategic and growth analysis

Nektar

Pipeline

Strategic and growth analysis

Key M&A and licensing activity

Drug delivery business strategy

M&A activity in drug delivery

Chapter 8 The future of drug delivery

Summary

Introduction

Nanotechnology

siRNA

Stem cells

Transmucosal drug delivery

Conclusions and key findings

Chapter 9 Appendix

IMS data

Bibliography

Index

List of Figures

Figure 1.1: Drivers of innovation in drug delivery

Figure 2.2: Sales of Abraxane, Taxol and generic paclitaxol in the US and 5EU, 2005-6

Figure 2.3: Doxil structure

Figure 3.4: Targeted oncology pipeline by indication, 2006

Figure 3.5: Sales of marketed oncology mAbs, 2004-5

Figure 4.6: Inhaled insulin market forecast, 2006-2015

Figure 4.7: Aradigm pain management AERx device

Figure 4.8: Sales forecasts of MedImmunes FluMist and CAIV-T in the US, 2004-2011

Figure 5.9: Transdermal drug delivery pipeline by therapy area, 2006

Figure 5.10: ALZA’s E-TRANS delivery system

Figure 6.11: Biophan’s nanomagnetic particle-based technology

Figure 7.12: Capabilities of leading innovative drug delivery companies, 2006

Figure 7.13: Licensing and collaboration strategy of leading innovative drug delivery companies

List of Tables

Table 1.1: Key companies specializing in long-acting injection technology

Table 2.2: Nanoparticles as drug delivery carriers

Table 2.3: Sales of cancer nanomedicine marketed products in the US and 5EU, 2005-6

Table 2.4: Key nanotechnology/nanomedicine deals, 2005-2006

Table 2.5: Sales of marketed products using Elan’s NanoCrystal technology in the US and 5EU,

2005-6

Table 2.6: Flamel’s product pipeline using the Medusa platform, 2006

Table 3.7: Key pipeline oncology drugs using nanotechnology, 2006

Table 3.8: Late stage oncology monoclonal antibody pipeline, 2006

Table 3.9: Antibody fragment pipeline, 2006

Table 3.10: Chemotherapeutic siRNA targets

Table 4.11: Key pulmonary/inhalable delivery pipeline, 2006

Table 4.12: Key pulmonary insulin pipeline, 2006

Table 5.13: Key late-stage transdermal patches, 2006

Table 5.14: Transdermal patch technology companies, 2006

Table 6.15: Key clinical trial with drug-eluting stents, 2006

Table 6.16: Comparison of costs for bare-metal and drug-eluting coronary stents, 2004

Table 6.17: Drug eluting stent pipeline, 2006

Table 7.18: Altea Therapeutic’s pipeline, 2006

Table 7.19: ALZA’s core technologies, 2006

Table 7.20: ALZA Therapeutics’ pipeline, 2006

Table 7.21: ALZA’s drug delivery deals, 2005-6

Table 7.22: Elan’s R&D pipeline, 2006

Table 7.23: Elan’s drug delivery deals, 2005-6

Table 7.24: Emisphere’s pipeline, 2006

Table 7.25: Emisphere’s drug delivery deals, 2005-6

Table 7.26: Nektar’s key innovative pipeline products, 2006

Table 7.27: Nektar Therapeutics’ drug delivery deals, 2005-6

Table 7.28: Drug discovery and technology deals made by the top 20 pharmaceutical companies,

2000–04

Table 7.29: Key drug delivery M&A activity, 2006